Corvus Pharmaceuticals to Present at the 2017 Wedbush PacGrow Healthcare Conference
August 11 2017 - 7:10PM
Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of novel immuno-oncology therapies, today
announced that the company will present at the 2017 Wedbush PacGrow
Healthcare Conference in New York City, New York. The presentation
is scheduled for Wednesday, August 16, at 1:20pm Eastern Time.
A webcast of the presentation will be available live and for 30
days following the event. The webcast may be accessed via
http://wsw.com/webcast/wedbush33/crvs and from the investor
relations section of the Corvus website.
About Corvus Pharmaceuticals Corvus
Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on the development and commercialization of small molecule
and antibody agents that target the immune system to treat patients
with cancer. These agents block or modify crucial immune
checkpoints and reprogram immune T-cells. Corvus’ lead product,
CPI-444, is a checkpoint inhibitor that is designed to disable a
tumor’s ability to subvert attack by the immune system by
inhibiting adenosine in the tumor microenvironment. CPI-444 is a
small molecule that is taken orally. CPI-444 is currently being
evaluated in a multicenter Phase 1/1b clinical trial in patients
with various solid tumors. This successive expansion cohort trial
is examining the activity of CPI-444 both as a single agent and in
combination with Genentech’s Tecentriq® (atezolizumab), an
anti-PD-L1 antibody. Corvus is conducting the trial with Genentech,
a member of the Roche Group, under a clinical trial collaboration
the two companies entered into in October 2015. For more
information, visit: www.corvuspharma.com.
Tecentriq® (atezolizumab) is a registered trademark of
Genentech.
Corvus Contact:
Guillermo Elias, PhD
Director, Business Development
Corvus Pharmaceuticals, Inc.
+1-650-889-4377
GElias@corvuspharma.com
Media Contact:
Julie Normart
Pure Communications
+1-415-946-1087
jnormart@purecommunications.com
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Apr 2024 to May 2024
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From May 2023 to May 2024